C4 Therapeutics (CCCC) Change in Receivables (2019 - 2026)
C4 Therapeutics' quarterly Change in Receivables came in at $482000.0 in Q1 2026, down 90.22% year-on-year from $4.9 million in Q1 2025, and up 111.64% quarter-over-quarter from -$4.1 million in Q4 2025.
C4 Therapeutics has reported Change in Receivables for 8 years, with the latest figure at $482000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Receivables fell 90.22% year-over-year to $482000.0; the trailing twelve-month figure through Mar 2026 stood at -$5.1 million (up 7.63% YoY), and the FY2025 full-year result was -$701000.0, up 91.94% from the prior year.
- Change in Receivables for Q1 2026 stood at $482000.0, up from -$4.1 million in the prior quarter.
- The five-year high for Change in Receivables was $11.3 million in Q4 2023, with the low at -$12.4 million in Q2 2024.
- Average Change in Receivables over 5 years is -$166647.1, with a median of -$63000.0 recorded in 2022.
- Year-over-year, Change in Receivables surged 75433.33% in 2023 and sank 2586.2% in 2024.
- Tracing CCCC's Change in Receivables over 5 years: stood at -$15000.0 in 2022, then surged by 75433.33% to $11.3 million in 2023, then tumbled by 164.06% to -$7.2 million in 2024, then soared by 42.8% to -$4.1 million in 2025, then jumped by 111.64% to $482000.0 in 2026.
- The last three Change in Receivables figures came in at $482000.0 (Q1 2026), -$4.1 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 208,524.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -39.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -1.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 110.42 Mn |
| 10 | C4 Therapeutics | 561.03 Mn | 325.36 Mn | - | 482,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 482,000.00 |
| Mar 31, 2026 | 482,000.00 |
| Dec 31, 2025 | -4.14 Mn |
| Dec 31, 2025 | -4.14 Mn |
| Sep 30, 2025 | 4.34 Mn |
| Sep 30, 2025 | 4.34 Mn |
| Jun 30, 2025 | -5.83 Mn |
| Jun 30, 2025 | -5.83 Mn |
| Mar 31, 2025 | 4.93 Mn |
| Mar 31, 2025 | 4.93 Mn |
| Dec 31, 2024 | -7.24 Mn |
| Dec 31, 2024 | -7.24 Mn |
| Sep 30, 2024 | 9.17 Mn |
| Sep 30, 2024 | 9.17 Mn |
| Jun 30, 2024 | -12.43 Mn |
| Jun 30, 2024 | -12.43 Mn |
| Mar 31, 2024 | 1.80 Mn |
| Mar 31, 2024 | 1.80 Mn |
| Dec 31, 2023 | 11.30 Mn |
| Dec 31, 2023 | 11.30 Mn |
| Sep 30, 2023 | -528,000.00 |
| Sep 30, 2023 | -528,000.00 |
| Jun 30, 2023 | 500,000.00 |
| Jun 30, 2023 | 500,000.00 |
| Mar 31, 2023 | -945,000.00 |
| Mar 31, 2023 | -945,000.00 |
| Dec 31, 2022 | -15,000.00 |
| Dec 31, 2022 | -15,000.00 |
| Sep 30, 2022 | -222,000.00 |
| Sep 30, 2022 | -222,000.00 |
| Jun 30, 2022 | -63,000.00 |
| Jun 30, 2022 | -63,000.00 |
| Mar 31, 2022 | -3.94 Mn |
| Mar 31, 2022 | -3.94 Mn |
| Dec 31, 2021 | 871,000.00 |
| Dec 31, 2021 | 871,000.00 |
| Sep 30, 2021 | -1.37 Mn |
| Sep 30, 2021 | -1.37 Mn |
| Jun 30, 2021 | 2.56 Mn |
| Jun 30, 2021 | 2.56 Mn |
| Mar 31, 2021 | -828,000.00 |
| Mar 31, 2021 | -828,000.00 |
| Dec 31, 2020 | 343,000.00 |
| Dec 31, 2020 | 343,000.00 |
| Sep 30, 2020 | -4.41 Mn |
| Sep 30, 2020 | -4.41 Mn |
| Jun 30, 2020 | 5.23 Mn |
| Jun 30, 2020 | 5.23 Mn |
| Mar 31, 2020 | -1.30 Mn |
| Mar 31, 2020 | -1.30 Mn |
| Dec 31, 2019 | 2.03 Mn |
| Dec 31, 2019 | 2.03 Mn |